David Myles Sells 10,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider David Myles sold 10,000 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $28.34, for a total transaction of $283,400.00. Following the completion of the sale, the insider directly owned 144,846 shares of the company’s stock, valued at approximately $4,104,935.64. This trade represents a 6.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Olema Pharmaceuticals Stock Performance

Shares of OLMA stock opened at $29.19 on Friday. The stock’s 50-day moving average is $24.70 and its two-hundred day moving average is $13.11. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -15.61 and a beta of 1.92. Olema Pharmaceuticals, Inc. has a 1 year low of $2.86 and a 1 year high of $36.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its earnings results on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on OLMA. Citigroup increased their price target on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. UBS Group assumed coverage on shares of Olema Pharmaceuticals in a report on Wednesday, January 7th. They issued a “buy” rating and a $45.00 target price for the company. JPMorgan Chase & Co. raised their price target on Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Guggenheim assumed coverage on Olema Pharmaceuticals in a research report on Wednesday, October 8th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Piper Sandler started coverage on Olema Pharmaceuticals in a research note on Wednesday, January 7th. They set an “overweight” rating and a $40.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $41.00.

Key Stories Impacting Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Broker upgrades and higher price targets from multiple firms (Citigroup, Oppenheimer, Piper Sandler, Goldman Sachs) lifted analyst support and raised consensus upside (average target ≈ $41), which likely boosted investor confidence. MarketBeat Analyst Coverage
• Positive Sentiment: Olema published an investor presentation emphasizing its palazestrant (OP‑1250) development strategy and combination plans with CDK4/6 inhibitors — useful context for upcoming data and commercial potential that can support the stock. Investor Presentation
• Neutral Sentiment: Institutional ownership is very high (~91.8%), and a mix of recent modest institutional buys/sells was reported — this large institutional base can amplify moves but is not an immediate directional catalyst. Institutional Holdings
• Negative Sentiment: Significant insider selling was disclosed this week: Shane Kovacs sold 100,000 shares (~$2.87M at $28.73) and additional smaller lots; Director/insider David Myles sold multiple blocks (including 50,000 at ~$27.60 and 10,000 at ~$28.34). Large insider sales (noted ownership percentage drops) can weigh on sentiment even if management retains meaningful stakes. Kovacs SEC Filing Myles SEC Filing

Institutional Investors Weigh In On Olema Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in OLMA. Nisa Investment Advisors LLC increased its position in Olema Pharmaceuticals by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after purchasing an additional 477 shares during the period. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Olema Pharmaceuticals by 83.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 447,046 shares of the company’s stock valued at $11,176,000 after buying an additional 202,970 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Olema Pharmaceuticals in the fourth quarter valued at approximately $1,735,000. Susquehanna International Group LLP grew its holdings in Olema Pharmaceuticals by 20.6% during the third quarter. Susquehanna International Group LLP now owns 112,277 shares of the company’s stock worth $1,099,000 after acquiring an additional 19,182 shares during the period. Finally, Quarry LP acquired a new position in Olema Pharmaceuticals during the third quarter worth $184,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.